Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis' Purchase Of Eon Clears FTC; Amide Gets Three Divested Generics

This article was originally published in The Pink Sheet Daily

Executive Summary

The company gains final regulatory approval of its deal for Eon with an agreement to divest three generics to Amide. FTC’s proposed consent order instructs generic subsidiary Sandoz to supply two of the drugs – antidepressant desipramine and muscle relaxant orphenadrine – until Amide receives FDA manufacturing clearance.

You may also be interested in...

Watson/Actavis Merger Requires Near Record Divestiture; Sandoz, Par Pick Up 18 Products

The required divestitures are quite significant relative to the size of the transaction: this is the second-largest divesture, but only the fifth-largest merger of generic firms.

Actavis Enters U.S. Generic Market Through $500 Mil. Amide Acquisition

Iceland-based Actavis will diversify its European-centric revenue base through the acquisition of Amide, located in New Jersey. An Amide manufacturing site currently under construction and slated for completion in 2006 could significantly boost U.S. capacity for the combined companies.

Novartis Boosts Sandoz Generic Business With Acquisition Of Eon, Hexal

Addition of U.S., German companies will make Sandoz the global leader in generic sales, with combined 2004 pro forma revenues of $5.1 bil., Novartis says. Acquisition will enable Sandoz to become the "preferred partner" for "authorized" generic deals and to play a leading role in development of follow-on biologics.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts